Lantheus Holdings (LNTH) EBITDA Margin (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly EBITDA Margin came in at 21.55% in Q1 2026, down 583.0% year-on-year from 4.46% in Q1 2025, and up 13.59% on a QoQ basis from 18.97% in Q4 2025.
Lantheus Holdings (LNTH) EBITDA Margin (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of EBITDA Margin data on file, last reported at 21.55% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 583.0% year-over-year to 21.55% in Q1 2026; TTM through Mar 2026 was 18.76%, a 1068.0% decrease from a year earlier, with the FY2025 full-year figure at 20.16%, down 963.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 21.55%, up from 18.97% in the prior quarter.
- Over the last five years, EBITDA Margin for LNTH reached as high as 916.57% in Q4 2023 and fell as low as 65.24% in Q4 2022.
- Historically, EBITDA Margin has averaged 72.71% across 5 years, with a median of 28.21% in 2022.
- Across the five-year window, EBITDA Margin surged 98181 bps in 2023 and sank 88746 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 65.24% in 2022, then surged by 1505 bps to 916.57% in 2023, then sank by 97 bps to 29.12% in 2024, then tumbled by 35 bps to 18.97% in 2025, then advanced by 14 bps to 21.55% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 21.55% in Q1 2026, 18.97% in Q4 2025, and 11.36% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 21.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.55% |
| Dec 31, 2025 | 18.97% |
| Sep 30, 2025 | 11.36% |
| Jun 30, 2025 | 23.27% |
| Mar 31, 2025 | 27.38% |
| Dec 31, 2024 | 29.12% |
| Sep 30, 2024 | 35.31% |
| Jun 30, 2024 | 26.07% |
| Mar 31, 2024 | 28.82% |
| Dec 31, 2023 | 916.57% |
| Sep 30, 2023 | 35.12% |
| Jun 30, 2023 | 38.59% |
| Mar 31, 2023 | -3.11% |
| Dec 31, 2022 | -65.24% |
| Sep 30, 2022 | 35.83% |
| Jun 30, 2022 | 28.25% |
| Mar 31, 2022 | 28.21% |
| Dec 31, 2021 | -27.27% |
| Sep 30, 2021 | -14.04% |
| Jun 30, 2021 | -26.50% |